OCULAR PHARMACOKINETICS OF ORALLY-ADMINISTERED AZITHROMYCIN IN RABBITS

被引：11

作者：

ODAY, DM

HEAD, WS

FOULDS, G

ROBINSON, RD

WILLIAMS, TE

FERRAINA, RA

机构：

[1] Department of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, Tennessee

[2] Pfizer Central Research, Inc., Groton, Connecticut

来源：

JOURNAL OF OCULAR PHARMACOLOGY | 1994年 / 10卷 / 04期

关键词：

D O I：

10.1089/jop.1994.10.633

中图分类号：

R77 [眼科学];

学科分类号：

100212 ;

摘要：

Azithromycin was orally administered to Dutch-belted rabbits following extracapsular lens extraction in one eye. At various times the animals were sacrificed, and serum and ocular tissues were obtained for drug level determination by HPLC-EC. Following a single dose, peak levels of drug in ocular tissues were measured within 8 hours (cornea > 0.5 mu g/g [15mg/kg]; > 1.5 mu g/g [30mg/kg]). Highest levels were obtained in iris and ciliary body( > 15 mu g). Measurable tissue levels persisted for at least 120 hours. Trough levels increased proportionately during drug multiple dose administration. Five days following five daily 15mg/kg doses, corneal levels exceeded 0.5 mu g/g, and iris and ciliary levels were higher than 15 mu g/g. Aqueous humor and serum levels were equivalent. Vitreous humor levels, though higher than aqueous humor, were consistently < 1 mu g/ml. Extracapsular cataract extraction did not significantly affect drug uptake.

引用

页码：633 / 641

页数：9

共 23 条

[1]

Bright G.M., Nagle A.A., Bordner J., Et al., Synthesis and in vitro and in vivo activity of novel 9-deoxy-9a-AZA-9a homo erythromycin A derivatives

[2]

a new class of macrolide antibiotics, the azalides, J. Antibiot., 41, pp. 1029-1047, (1988)

[3]

Retsema J., Girard A., Schelky W., Et al., Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered ring macrolide with improved potency against gram negative organisms. Antimicrob, Agents Chemother., 31, pp. 1939-1947, (1987)

[4]

Walsh M., Kappus E.W., Quinn T.C., In vitro evaluation of CP-62,993, erythromycin, clindamycin and tetracycline against Chlamydia trachomatis, Antimicrob. Agents Chemother., 31, pp. 811-812, (1987)

[5]

Williams J.D., Spectrum of activity of azithromycin, Europ. J. Clin. Microbiol. Inf. Dis., 10, pp. 813-820, (1991)

[6]

Araujo F.G., Guptill D.R., Remington J.S., Azithromycin, a macrolide antibiotic with potent activity against Toxoplasma gondii, Antimicrob. Agents Chemother., 32, pp. 755-757, (1988)

[7]

Foulds G., Shepard R.M., Johnson R.B., The pharmacokinetics of azithromycin in human serum and tissues, J. Antimicrob. Chemother., 25, pp. 73-82, (1990)

[8]

Coates P., Daniel R., Houston A.C., Antrobus J.H.L., Taylor T., An open study to compare the pharmacokinetics, safety, and tolerability of a multiple-dose regimen of azithromycin in young and elderly volunteers, Europ. J. Clin. Microbiol. Inf. Dis., 10, pp. 850-852, (1991)

[9]

Foulds G., Chan K.H., Johnson J.T., Shepard R.M., Johnson R.B., Concentrations of azithromycin in human tonsillar tissue, Europ. J. Clin. Microbiol. Inf. Dis., 10, pp. 853-856, (1991)

[10]

Karma P., Pukander J., Penttila M., Azithromycin concentrations in sinus fluid and mucosa after oral administration, Europ. J. Clin. Microbiol. Inf. Dis., 10, pp. 856-859, (1991)

← 1 2 3 →